Endovascular thrombectomy and intravenous alteplase in patients with acute ischemic stroke due to large vessel occlusion : A clinical practice guideline
© 2022 Chinese Cochrane Center, West China Hospital of Sichuan University and John Wiley & Sons Australia, Ltd..
AIM: Whether or not use of intravenous alteplase in combination with endovascular thrombectomy (EVT) improves outcomes versus EVT alone, for acute stroke patients with large vessel occlusion presenting directly to a comprehensive stroke center, is uncertain.
METHODS: Six randomized trials exploring this issue were published, and we synthesized this evidence to inform a rapid guideline based on the Guidelines International Network principles and guided by the GRADE approach.
RESULTS: We enlisted an international panel that included 4 patient partners and 1 caregiver, individuals from 6 countries. The panel considered low certainty evidence that EVT alone, relative to EVT with intravenous alteplase, possibly results in a small decrease in the proportion of patients that achieve functional independence and possibly a small increase in mortality. Both effect estimates were downgraded twice due to very serious imprecision. The panel also considered moderate certainty evidence that EVT alone probably decreases symptomatic intracranial hemorrhage, versus EVT with alteplase, and combination therapy was more costly than EVT alone. As a result of the low certainty for improved recovery without impairment and mortality for combination therapy versus EVT alone, and moderate certainty for increased harm with combination therapy, the panel made a weak recommendation in favor of EVT alone for stroke patients eligible for both treatments, and initially presenting directly to a comprehensive stroke center that provides both treatments.
CONCLUSIONS: Consistent with this weak recommendation, optimal patient management will likely often include co-treatment with intravenous alteplase, depending on local circumstances and patient presentation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Journal of evidence-based medicine - 15(2022), 3 vom: 01. Sept., Seite 263-271 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ye, Zhikang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alteplase |
|---|
| Anmerkungen: |
Date Completed 04.10.2022 Date Revised 04.10.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/jebm.12493 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346402670 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346402670 | ||
| 003 | DE-627 | ||
| 005 | 20231226031348.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jebm.12493 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1154.xml |
| 035 | |a (DE-627)NLM346402670 | ||
| 035 | |a (NLM)36123777 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ye, Zhikang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Endovascular thrombectomy and intravenous alteplase in patients with acute ischemic stroke due to large vessel occlusion |b A clinical practice guideline |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.10.2022 | ||
| 500 | |a Date Revised 04.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 Chinese Cochrane Center, West China Hospital of Sichuan University and John Wiley & Sons Australia, Ltd. | ||
| 520 | |a AIM: Whether or not use of intravenous alteplase in combination with endovascular thrombectomy (EVT) improves outcomes versus EVT alone, for acute stroke patients with large vessel occlusion presenting directly to a comprehensive stroke center, is uncertain | ||
| 520 | |a METHODS: Six randomized trials exploring this issue were published, and we synthesized this evidence to inform a rapid guideline based on the Guidelines International Network principles and guided by the GRADE approach | ||
| 520 | |a RESULTS: We enlisted an international panel that included 4 patient partners and 1 caregiver, individuals from 6 countries. The panel considered low certainty evidence that EVT alone, relative to EVT with intravenous alteplase, possibly results in a small decrease in the proportion of patients that achieve functional independence and possibly a small increase in mortality. Both effect estimates were downgraded twice due to very serious imprecision. The panel also considered moderate certainty evidence that EVT alone probably decreases symptomatic intracranial hemorrhage, versus EVT with alteplase, and combination therapy was more costly than EVT alone. As a result of the low certainty for improved recovery without impairment and mortality for combination therapy versus EVT alone, and moderate certainty for increased harm with combination therapy, the panel made a weak recommendation in favor of EVT alone for stroke patients eligible for both treatments, and initially presenting directly to a comprehensive stroke center that provides both treatments | ||
| 520 | |a CONCLUSIONS: Consistent with this weak recommendation, optimal patient management will likely often include co-treatment with intravenous alteplase, depending on local circumstances and patient presentation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a alteplase | |
| 650 | 4 | |a clinical practice guideline | |
| 650 | 4 | |a endovascular thrombectomy | |
| 650 | 4 | |a stroke | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 650 | 7 | |a Tissue Plasminogen Activator |2 NLM | |
| 650 | 7 | |a EC 3.4.21.68 |2 NLM | |
| 700 | 1 | |a Busse, Jason W |e verfasserin |4 aut | |
| 700 | 1 | |a Hill, Michael D |e verfasserin |4 aut | |
| 700 | 1 | |a Lindsay, M Patrice |e verfasserin |4 aut | |
| 700 | 1 | |a Guyatt, Gordon H |e verfasserin |4 aut | |
| 700 | 1 | |a Prasad, Kameshwar |e verfasserin |4 aut | |
| 700 | 1 | |a Agarwal, Arnav |e verfasserin |4 aut | |
| 700 | 1 | |a Beattie, Cheryl |e verfasserin |4 aut | |
| 700 | 1 | |a Beattie, Jim |e verfasserin |4 aut | |
| 700 | 1 | |a Dodd, Cynthia |e verfasserin |4 aut | |
| 700 | 1 | |a Heran, Manraj K S |e verfasserin |4 aut | |
| 700 | 1 | |a Narayan, Sunil |e verfasserin |4 aut | |
| 700 | 1 | |a Chartúir, Norita Ní |e verfasserin |4 aut | |
| 700 | 1 | |a O'Donnell, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Resmini, Ilaria |e verfasserin |4 aut | |
| 700 | 1 | |a Sacco, Simona |e verfasserin |4 aut | |
| 700 | 1 | |a Sylaja, P N |e verfasserin |4 aut | |
| 700 | 1 | |a Volders, David |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Zachrison, Kori S |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Lingli |e verfasserin |4 aut | |
| 700 | 1 | |a Zhong, Hongliang |e verfasserin |4 aut | |
| 700 | 1 | |a An, Zhuoling |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Eric E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of evidence-based medicine |d 2008 |g 15(2022), 3 vom: 01. Sept., Seite 263-271 |w (DE-627)NLM206067801 |x 1756-5391 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2022 |g number:3 |g day:01 |g month:09 |g pages:263-271 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jebm.12493 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2022 |e 3 |b 01 |c 09 |h 263-271 | ||